# EDGAR Filing Document

**Accession Number:** 0001156039
**File Stem:** 0001193125-23-019221
**Filing Date:** 2023-1
**Character Count:** 8944
**Document Hash:** 9a40534e283610f0b3b59b2b3aac1128
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-23-019221.hdr.sgml**: 20230130

**ACCESSION NUMBER**: 0001193125-23-019221

**CONFORMED SUBMISSION TYPE**: FWP

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20230130

**DATE AS OF CHANGE**: 20230130

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Elevance Health, Inc.
- **CENTRAL INDEX KEY:** 0001156039
- **STANDARD INDUSTRIAL CLASSIFICATION:** HOSPITAL & MEDICAL SERVICE PLANS [6324]
- **IRS NUMBER:** 352145715
- **STATE OF INCORPORATION:** IN
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** FWP
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 333-249877
- **FILM NUMBER:** 23569146

**BUSINESS ADDRESS:**
- **STREET 1:** 220 VIRGINIA AVENUE
- **CITY:** INDIANAPOLIS
- **STATE:** IN
- **ZIP:** 46204
- **BUSINESS PHONE:** 8003311476

**MAIL ADDRESS:**
- **STREET 1:** 220 VIRGINIA AVENUE
- **CITY:** INDIANAPOLIS
- **STATE:** IN
- **ZIP:** 46204

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Anthem, Inc.
- **DATE OF NAME CHANGE:** 20141202

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** WELLPOINT, INC
- **DATE OF NAME CHANGE:** 20100105

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** WELLPOINT INC
- **DATE OF NAME CHANGE:** 20041130
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Elevance Health, Inc.
- **CENTRAL INDEX KEY:** 0001156039
- **STANDARD INDUSTRIAL CLASSIFICATION:** HOSPITAL & MEDICAL SERVICE PLANS [6324]
- **IRS NUMBER:** 352145715
- **STATE OF INCORPORATION:** IN
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** FWP

**BUSINESS ADDRESS:**
- **STREET 1:** 220 VIRGINIA AVENUE
- **CITY:** INDIANAPOLIS
- **STATE:** IN
- **ZIP:** 46204
- **BUSINESS PHONE:** 8003311476

**MAIL ADDRESS:**
- **STREET 1:** 220 VIRGINIA AVENUE
- **CITY:** INDIANAPOLIS
- **STATE:** IN
- **ZIP:** 46204

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Anthem, Inc.
- **DATE OF NAME CHANGE:** 20141202

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** WELLPOINT, INC
- **DATE OF NAME CHANGE:** 20100105

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** WELLPOINT INC
- **DATE OF NAME CHANGE:** 20041130

**Free Writing Prospectus Filed Pursuant to Rule 433** 

**To Prospectus dated November 5, 2020** 

**Preliminary Prospectus Supplement dated January 30, 2023** 

**Registration Statement File No. 333-249877** 

**ELEVANCE HEALTH, INC.** 

**Offering of:** 

**$500,000,000 4.900% Notes due 2026 (the "2026 Notes")** 

**$1,000,000,000 4.750% Notes due 2033 (the "2033 Notes")** 

**$1,100,000,000 5.125% Notes due 2053 (the "2053 Notes")** 

**Pricing Term Sheet dated** 

**January 30, 2023** 

------

*The information in this pricing term sheet relates to the Offering and should be read together with the preliminary prospectus supplement dated January 30, 2023 (the "Preliminary Prospectus Supplement"), including the documents incorporated by reference therein and the related base prospectus dated November 5, 2020, filed pursuant to Rule 424(b) under the Securities Act of 1933, as amended (Registration Statement File No. 333-249877). Terms used but not defined herein, with respect to the Offering, have the meanings ascribed to them in the Preliminary Prospectus Supplement.* 

------

---

| | |
|:---|:---|
| Company | Elevance Health, Inc., an Indiana corporation |
| Ratings\* | Baa2 / A / BBB (Moody's / S&P / Fitch) |
| Pricing Date | January 30, 2023 |
| Trade Date | January 30, 2023 |
| Settlement Date | February 8, 2023 (T+7) |
| Aggregate Principal Offering Amount | $500,000,000 for the 2026 Notes<br> $1,000,000,000 for the 2033 Notes<br> $1,100,000,000 for the 2053 Notes |
| Maturity Date | February 8, 2026 for the 2026 Notes<br> February 15, 2033 for the 2033 Notes<br> February 15, 2053 for the 2053 Notes |
| Coupon (Interest Rate) | 4.900% for the 2026 Notes<br> 4.750% for the 2033 Notes<br> 5.125% for the 2053 Notes |
| Price to Public (Issue Price) | 99.895% of the principal amount for the 2026 Notes<br> 99.841% of the principal amount for the 2033 Notes<br> 99.634% of the principal amount for the 2053 Notes |
| Yield to Maturity | 4.938% for the 2026 Notes<br> 4.770% for the 2033 Notes<br> 5.149% for the 2053 Notes |
| Spread to Benchmark Treasury | T + 97 basis points for the 2026 Notes<br> T + 122 basis points for the 2033 Notes<br> T + 147 basis points for the 2053 Notes |

---

------

---

| | |
|:---|:---|
| Benchmark Treasury | 3.875% due January 15, 2026 for the 2026 Notes<br> 4.125% due November 15, 2032 for the 2033 Notes<br> 3.000% due August 15, 2052 for the 2053 Notes |
| Benchmark Treasury Price / Yield | 99-23 <sup>3</sup>⁄<sub>4</sub> / 3.968% for the 2026 Notes<br> 104-23 / 3.550% for the 2033 Notes<br> 87-26+ / 3.679% for the 2053 Notes |
| Interest Payment Dates | February 8 and August 8, commencing August 8, 2023 for the 2026 Notes<br> February 15 and August 15, commencing August 15, 2023 for the 2033 Notes<br> February 15 and August 15, commencing August 15, 2023 for the 2053 Notes |
| Optional Redemption Provisions | For the 2026 Notes: Prior to February 8, 2024 (the date that is 2 years prior to the maturity date), make-whole call at Treasury rate plus 15 basis points; par call at any time on or after February 8, 2024.<br>For the 2033 Notes: Prior to November 15, 2032 (the date that is 3 months prior to the maturity date), make-whole call at Treasury rate plus 20 basis points; par call at any time on or after November 15, 2032.<br>For the 2053 Notes: Prior to August 15, 2052 (the date that is six months prior to the maturity date), make-whole call at Treasury rate plus 25 basis points; par call at any time on or after August 15, 2052. |
| Denomination | $1,000 and integral multiples of $1,000 in excess thereof |
| Day Count Convention | 30/360 |
| Payment Business Days | New York |
| CUSIP/ISIN Number | 28622H AA9 / US28622HAA95 for the 2026 Notes<br> 28622H AB7 / US28622HAB78 for the 2033 Notes<br> 28622H AC5 / US28622HAC51 for the 2053 Notes |
| Joint Book-Running Managers | Goldman Sachs & Co. LLC<br> Barclays Capital Inc.<br> J.P. Morgan Securities LLC |
| Passive Book-Running Managers | Citigroup Global Markets Inc.<br> Mizuho Securities USA LLC |
| Senior Co-Managers | BofA Securities, Inc.<br> Credit Suisse Securities (USA) LLC<br> Deutsche Bank Securities Inc.<br> Morgan Stanley & Co. LLC<br> PNC Capital Markets LLC<br> Truist Securities, Inc.<br> U.S. Bancorp Investments, Inc.<br> Wells Fargo Securities, LLC |
| Junior Co-Managers | BNY Mellon Capital Markets, LLC<br> Huntington Securities, Inc. |

---

**\*** **Note: A securities rating is not a recommendation to buy, sell or hold securities and may be subject to revision or withdrawal at any time.** 

------

**It is expected that delivery of the notes will be made against payment thereof on or about February 8, 2023, which will be the seventh business day following the pricing of the notes (such settlement being referred to as "T+7"). Under Rule 15c6-1 under the Exchange Act, trades in the secondary market are generally required to settle in two business days, unless the parties to any such trade expressly agree otherwise. Accordingly, purchasers who wish to trade notes on the date hereof or the next succeeding four business days will be required, by virtue of the fact that the notes will initially settle in T+7, to specify an alternate settlement arrangement at the time of any such trade to prevent a failed settlement.** 

**The issuer has filed a registration statement (including a prospectus) with the SEC for the offering to which this communication relates (File No. 333-249877). Before you invest, you should read the prospectus in that registration statement and other documents the issuer has filed with the SEC for more complete information about the issuer and the Offering. You may get these documents for free by visiting EDGAR on the SEC Website at www.sec.gov. Alternatively, the issuer, any underwriter or any dealer participating in the Offering will arrange to send you the base prospectus and the Preliminary Prospectus Supplement if you request them by calling (i) Goldman Sachs & Co. LLC at 1-(866) 471-2526, (ii) Barclays Capital Inc. at 1-(888) 603-5847, or (iii) J.P. Morgan Securities LLC at (212) 834-4533.** 

**This communication should be read in conjunction with the Preliminary Prospectus Supplement and the accompanying base prospectus. The information in this communication supersedes the information in the Preliminary Prospectus Supplement and the accompanying base prospectus to the extent inconsistent with the information in the Preliminary Prospectus Supplement and the accompanying base prospectus.** 

**ANY DISCLAIMERS OR OTHER NOTICES THAT MAY APPEAR BELOW ARE NOT APPLICABLE TO THIS COMMUNICATION AND SHOULD BE DISREGARDED. SUCH DISCLAIMERS OR OTHER NOTICES WERE AUTOMATICALLY GENERATED AS A RESULT OF THIS COMMUNICATION BEING SENT VIA BLOOMBERG OR ANOTHER EMAIL SYSTEM.**